317 related articles for article (PubMed ID: 8016763)
1. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society.
Thorax; 1994 May; 49(5):442-5. PubMed ID: 8016763
[TBL] [Abstract][Full Text] [Related]
2. First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol.
Research Committee of the British Thoracic Society
Thorax; 2001 Mar; 56(3):167-72. PubMed ID: 11182006
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary disease caused by M. malmoense in HIV negative patients: 5-yr follow-up of patients receiving standardised treatment.
Eur Respir J; 2003 Mar; 21(3):478-82. PubMed ID: 12662005
[TBL] [Abstract][Full Text] [Related]
4. Treatment with a macrolide-containing regimen for Mycobacterium kansasii pulmonary disease.
Moon SM; Choe J; Jhun BW; Jeon K; Kwon OJ; Huh HJ; Lee NY; Daley CL; Koh WJ
Respir Med; 2019 Mar; 148():37-42. PubMed ID: 30827472
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary disease caused by Mycobacterium xenopi in HIV-negative patients: five year follow-up of patients receiving standardised treatment.
Jenkins PA; Campbell IA;
Respir Med; 2003 Apr; 97(4):439-44. PubMed ID: 12693807
[TBL] [Abstract][Full Text] [Related]
6. Comparison of characteristics of patients and treatment outcome for pulmonary non-tuberculous mycobacterial infection and pulmonary tuberculosis.
Al Jarad N; Demertzis P; Jones DJ; Barnes NC; Rudd RM; Gaya H; Wedzicha JA; Hughes DT; Empey DW
Thorax; 1996 Feb; 51(2):137-9. PubMed ID: 8711643
[TBL] [Abstract][Full Text] [Related]
7. [Acquired rifampicin resistance during M. kansasii infection in a patient with AIDS].
Dautzenberg B; Antoun F; Truffot C
Rev Mal Respir; 1992; 9(4):464-6. PubMed ID: 1509191
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary infection with Mycobacterium kansasii in Wales, 1970-9: review of treatment and response.
Banks J; Hunter AM; Campbell IA; Jenkins PA; Smith AP
Thorax; 1983 Apr; 38(4):271-4. PubMed ID: 6867979
[TBL] [Abstract][Full Text] [Related]
9. [Two cases of pulmonary infection by Mycobacterium abscessus in which drug susceptibility testing results conflicted with clinical courses].
Nishizawa Y; Fujimura M; Tagami A; Abo M; Honjyo C; Yasui M; Nakao S
Nihon Kokyuki Gakkai Zasshi; 2005 Apr; 43(4):241-6. PubMed ID: 15966372
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary disease caused by Mycobacterium avium-intracellulare in HIV-negative patients: five-year follow-up of patients receiving standardised treatment.
Int J Tuberc Lung Dis; 2002 Jul; 6(7):628-34. PubMed ID: 12102303
[TBL] [Abstract][Full Text] [Related]
11. Clinical and epidemiological characteristics of M. kansasii pulmonary infections from Rio de Janeiro, Brazil, between 2006 and 2016.
Goldenberg T; Gayoso R; Mogami R; Lourenço MC; Ramos JP; Carvalho LD; Dalcolmo MP; Mello FCQ
J Bras Pneumol; 2020; 46(6):e20190345. PubMed ID: 32696934
[TBL] [Abstract][Full Text] [Related]
12. Rifampin-resistant Mycobacterium kansasii.
Wallace RJ; Dunbar D; Brown BA; Onyi G; Dunlap R; Ahn CH; Murphy DT
Clin Infect Dis; 1994 May; 18(5):736-43. PubMed ID: 8075262
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary Mycobacterium kansasii infection: comparison of the clinical features, treatment and outcome with pulmonary tuberculosis.
Evans SA; Colville A; Evans AJ; Crisp AJ; Johnston ID
Thorax; 1996 Dec; 51(12):1248-52. PubMed ID: 8994524
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy for pulmonary disease due to Mycobacterium kansasii: efficacies of some individual drugs.
Ahn CH; Lowell JR; Ahn SS; Ahn S; Hurst GA
Rev Infect Dis; 1981; 3(5):1028-34. PubMed ID: 7339800
[TBL] [Abstract][Full Text] [Related]
15. Mycobacterium kansasii: its presentation, treatment and outcome in HIV infected patients.
Rooney G; Nelson MR; Gazzard B
J Clin Pathol; 1996 Oct; 49(10):821-3. PubMed ID: 8943748
[TBL] [Abstract][Full Text] [Related]
16. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
17. [Clinical characteristics and drug susceptibility test of nontuberculous mycobacterial lung disease].
Lou H; Sun Q; Gu J; Yang H; Hao XH; Xiao HP; Sha W
Zhonghua Jie He He Hu Xi Za Zhi; 2019 Dec; 42(12):901-906. PubMed ID: 31826533
[No Abstract] [Full Text] [Related]
18. Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 vs 12 months' chemotherapy.
Sauret J; Hernández-Flix S; Castro E; Hernández L; Ausina V; Coll P
Tuber Lung Dis; 1995 Apr; 76(2):104-8. PubMed ID: 7780090
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary disease caused by Mycobacterium terrae complex.
Tonner JA; Hammond MD
South Med J; 1989 Oct; 82(10):1279-82. PubMed ID: 2678502
[TBL] [Abstract][Full Text] [Related]
20. [Nontuberculous Mycobacterial Pulmonary Disease - The New ATS/ERS/ESCMID/IDSA Guideline].
Wagner D; Lange C
Pneumologie; 2020 Nov; 74(11):773-779. PubMed ID: 33202438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
